Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody

Sang Il Kim, Sujeong Kim, Jung Min Shim, Hyo Jung Lee, So Young Chang, Seoryeong Park, Ji Young Min, Wan Beom Park, Myoung don Oh, Seungtaek Kim, Junho Chung

Research output: Contribution to journalArticlepeer-review


Zika virus (ZIKV) infection in both infants and adults is associated with neurological complications including, but not limited to, microcephaly and Guillain-Barre syndrome. Antibody therapy can be effective against virus infection. We isolated ZIKV envelope domain III-specific neutralizing antibodies (nAbs) from two convalescent patients with ZIKV infection. One antibody, 2F-8, exhibited potent in vitro neutralizing activity against Asian and American strains of ZIKV. To prevent FcγR-mediated antibody-dependent enhancement, we prepared IgG1 with LALA variation. A single dose of 2F–8 in the context of IgG1 or IgG1-LALA prior to or post lethal ZIKV challenge conferred complete protection in mice.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalBiochemical and Biophysical Research Communications
StatePublished - 19 Mar 2021


  • Antibody-dependent enhancement
  • Guillain-Barre syndrome
  • Microcephaly
  • Neutralizing antibody
  • Zika virus

Fingerprint Dive into the research topics of 'Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody'. Together they form a unique fingerprint.

Cite this